Streamlining the Journey to a Cure: Optimizing the Hepatitis C Virus Care Cascade

CMEO Webcast

Premiere Date: Wednesday, July 8, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other


Credit Expiration Date: Thursday, July 8, 2021

Begin Activity Now

Faculty


Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD (Moderator)
Director, Liver Institute Northwest
Clinical Professor, Elson S. Floyd College of Medicine
Washington State University
Spokane, WA

Scott C. Howell, DO Scott C. Howell, DO 
AIDS Healthcare Foundation
Los Angeles, CA

Anthony Martinez, MD, AAHIVS, FAASLD Anthony Martinez, MD, AAHIVS, FAASLD 
Associate Professor of Medicine
Jacobs School of Medicine
University at Buffalo
Medical Director, Hepatology
Erie County Medical Center
Buffalo, NY

Statement of Need

Hepatitis C virus (HCV) is a major cause of cirrhosis, liver cancer, and mortality worldwide. The opioid crisis has caused a rise in injection drug use, which has contributed significantly to the increase in HCV infections. The United States experienced a 238% increase in new HCV infections between 2010 and 2016, which has led to a goal to eliminate hepatitis by treating 80% of patients with hepatitis B virus (HBV) and HCV by 2030. The American Association for the Study of Liver Diseases/Infectious Disease Society of America (AASLD/IDSA) guidelines aim to achieve this with universal, one-time screening of all individuals over 18 for HCV, with individuals at increased risk (e.g., people who inject drugs [PWID]) screened more frequently, as well as universal testing of pregnant women at the initiation of prenatal care.

Once diagnosed, treatment with currently available direct-acting antivirals (DAAs) is strongly recommended for all persons with chronic HCV infection. However, recent studies have shown persistent gaps in the HCV care continuum, with underdiagnosis and undertreatment being the major barriers toward achieving the goal of eliminating HCV. With primary care clinicians and community health workers representing an important front-line resource for early screening and treatment for HCV infection, it is imperative to educate primary care providers (PCPs) and community health workers to expand the HCV workforce and linkage-to-care opportunities.

This CME Outfitters live and on-demand webcast will feature expert faculty hosting an interactive discussion on implementing HCV screening, developing new methods of coordinated care, and addressing barriers to treatment access.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Implement HCV screening for all adults and at-risk populations including PWID and women who are pregnant, in alignment with AASLD guidance.
  • Develop new methods of PCP/specialist coordinated care to minimize gaps in linkage to care and optimize the HCV care cascade.
  • Address barriers to access to treatment, such as stigma and HCP perceptions about substance use and PWID.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Explain HCV screening guidelines for all adults and at-risk populations including PWID and women who are pregnant, in alignment with AASLD guidance.
  • Identify new methods of PCP/specialist coordinated care to minimize gaps in linkage to care and optimize the HCV care cascade.
  • Describe barriers to access to treatment, such as stigma and HCP perceptions about substance use and PWID.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-20-103-L01-P
Enduring: 0376-0000-20-103-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kowdley reports that he receives research support from Conatus Pharmaceuticals Inc.; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Genfit; Gilead Sciences, Inc.; GlaxoSmithKline; HighTide Therapeutics Inc.; Intercept Pharmaceuticals, Inc.; and Zydus Pharmaceuticals, Inc. He is on the advisory committee for Assembly Biosciences, Inc.; Blade Therapeutics; Boehringer Ingelheim; Merck & Co, Inc.; and Roche. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.

Dr. Howell reports that he is a consultant for Echosens and Semler Scientific, Inc.

Dr. Martinez reports that he receives research support from AbbVie Inc.; Allergan; and Intercept Pharmaceuticals, Inc. He is on the advisory committee for AbbVie Inc.; and Gilead Sciences, Inc. He is on the speakers bureau for AbbVie Inc.; Dova Pharmaceuticals; Eisai Inc.; Gilead Sciences, Inc.; and Salix Pharmaceuticals.

Alaeddin Abukabda, MS, DMD, PhD (planning committee) has no disclosures to report.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TV-114-070820-47